keyword
MENU ▼
Read by QxMD icon Read
search

atrial fibrilation and coronary syndroms

keyword
https://www.readbyqxmd.com/read/29915905/antithromboembolic-strategies-for-patients-with-atrial-fibrillation-undergoing-percutaneous-coronary-intervention
#1
REVIEW
Ayesha Ather, Benjamin Laliberte, Brent N Reed, Ashley Schenk, Kristin Watson, Sandeep Devabhakthuni, Vincent Y See
We set out to synthesize available data on antithrombotic strategies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), with a focus on triple antithrombotic therapy (triple therapy [TT]; dual antiplatelet therapy plus an anticoagulant) versus dual therapy (DT; one antiplatelet agent and an anticoagulant). We searched OVID MEDLINE and PubMed from January 2005 to September 2017 using the search terms oral anticoagulant, triple therapy, dual therapy, acute coronary syndrome, percutaneous coronary intervention, and atrial fibrillation (limited to randomized controlled trials, observational studies, English language, minimum 6-12 months of follow-up, minimum 100 human patients)...
June 19, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29898844/an-open-label-2-%C3%A3-2-factorial-randomized-controlled-trial-to-evaluate-the-safety-of-apixaban-vs-vitamin-k-antagonist-and-aspirin-vs-placebo-in-patients-with-atrial-fibrillation-and-acute-coronary-syndrome-and-or-percutaneous-coronary-intervention-rationale
#2
Renato D Lopes, Amit N Vora, Danny Liaw, Christopher B Granger, Harald Darius, Shaun G Goodman, Roxana Mehran, Stephan Windecker, John H Alexander
BACKGROUND: The optimal antithrombotic strategy for patients with atrial fibrillation (AF) who develop acute coronary syndrome (ACS) and/or the need for percutaneous coronary intervention (PCI) is uncertain. The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events. DESIGN: AUGUSTUS is an international, multicenter randomized trial with a 2 × 2 factorial design to compare apixaban with vitamin K antagonists and aspirin with placebo in patients with AF who develop ACS and/or undergo PCI and are receiving a P2Y12 inhibitor...
June 2018: American Heart Journal
https://www.readbyqxmd.com/read/29894677/-the-quality-of-treatment-of-patients-with-atrial-fibrillation-depending-on-the-index-of-polymorbidity-preceded-hospitalization-for-acute-coronary-syndrome
#3
J A Dorofeeva, E I Tarlovskaya
The aim of this work was a retrospective assessment of the quality of treatment, depending on the severity of polymorbidity (PM) in patients with atrial fibrillation (AF) before admission to acute coronary syndrome (ACS). MATERIALS AND METHODS: Retrospectively, 105 patients were included in the analysis (54 men (51,4 %), mean age 65,94±9,34 years) who had AF before hospitalization for ACS. The index of polymorbidity (IPM) was assessed by ME Charlson et al. (1987) in the modification of H...
2018: Kardiologiia
https://www.readbyqxmd.com/read/29878086/adherence-to-dual-antiplatelet-therapy-with-ticagrelor-in-patients-with-acute-coronary-syndromes-treated-with-percutaneous-coronary-intervention-in-real-life-results-of-the-real-tica-registry
#4
Uwe Zeymer, Martin Cully, Mathias Hochadel
Aims: Little is known about the adherence to dual antiplatelet therapy with ticagrelor and reasons for discontinuation in real ife. Therefore we evaluated the 12-month course of patients with acute coronary syndromes (ACS) treated with percutaneous coronary intervention (PCI) and ticagrelor during the acute phase. Methods and results: A total of 614 patients included into the prospective ALKK-PCI Registry between 2014 and 2015 surviving for at least 12 months after discharge provided informations about duration of ticagrelor therapy...
June 7, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29877667/dapt-plus-anticoagulant-therapy-the-difficult-coexistence-post-acs-in-older-patients-with-atrial-fibrillation
#5
Mauro Di Bari, Alessandra Pratesi, Francesca M Nigro, Irene Marozzi, Stefano Fumagalli
Atrial fibrillation (AF) and coronary artery disease requiring percutaneous coronary intervention (PCI) and stenting often coexist in older patients. This poses the difficult problem of concurrent anticoagulant and double antiplatelet therapy (triple therapy). Current treatment guidelines do recommend triple therapy, especially in the course of acute coronary syndrome (ACS), with limitations due to an excessive risk of bleeding associated with this therapeutic regimen. This review summarizes randomized clinical trials and observational studies that compared triple therapy with a variety of different therapeutic options...
June 7, 2018: Monaldi Archives for Chest Disease, Archivio Monaldi Per le Malattie del Torace
https://www.readbyqxmd.com/read/29861295/stroke-prevention-1-year-clinical-outcomes-and-healthcare-resource-utilization-in-patients-with-atrial-fibrillation-in-france-data-from-the-garfield-af-registry
#6
Jean-Yves Le Heuzey, Jean-Pierre Bassand, Jean-Baptiste Berneau, Paolo Cozzolino, Lucia D'Angiolella, Bernard Doucet, Lorenzo G Mantovani, Michel Martelet, Joseph Mouallem, Jean-Joseph Muller, Karen Pieper
BACKGROUND: GARFIELD-AF is a non-interventional worldwide study of adults with atrial fibrillation. AIMS: To analyse the characteristics of the 1399 patients recruited in France from August 2010 to July 2015, their 1-year outcomes and healthcare resource utilization. METHOD: Patients aged ≥18 years with newly diagnosed atrial fibrillation (≤6 weeks' duration) and ≥1 stroke risk factor were eligible. Patient demographics, medical history and antithrombotic treatment were recorded at baseline...
May 31, 2018: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/29805414/intraventricular-dyssynchrony-among-patients-with-left-bundle-branch-block
#7
Abdul Sami, Malik Faisal Iftekhar, Imran Khan, Rafiullah Jan
Objective: To determine the frequency of intraventricular dyssynchrony among patients with left bundle branch block. Methods: The study was conducted at Hayatabad Medical Complex, Peshawar, from January, 2017 to July, 2017. All patients aged 18 years and above with Left Bundle Branch Block (LBBB) on ECG with or without heart failure were included in the study. Patients with valvular heart disease, predominant diastolic heart failure, acute coronary syndromes or coronary revascularization in last three months and atrial fibrillation were excluded...
March 2018: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29803897/uric-acid-and-cardiovascular-disease
#8
REVIEW
Gjin Ndrepepa
Uric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in humans. When present in cytoplasm of the cells or in acidic/hydrophobic milieu in atherosclerotic plaques, UA converts into a pro-oxidant agent and promotes oxidative stress and through this mechanism participates in the pathophysiology of human disease including cardiovascular disease (CVD). Most epidemiological studies but not all of them suggested the existence of an association between elevated serum UA level and CVD, including coronary heart disease (CHD), stroke, congestive heart failure, arterial hypertension and atrial fibrillation as well as an increased risk for mortality due to CVD in general population and subjects with confirmed CHD...
May 24, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29782287/-a-retrospective-analysis-of-the-quality-of-treatment-preceding-acute-coronary-syndrome-in-real-outpatient-practice-in-patients-with-atrial-fibrillation-local-register-data
#9
E I Tarlovskaya, J A Dorofeeva, S V Malcikova
AIM: To study retrospectively the treatment preceding acute coronary syndrome (ACS) in patients with atrial fibrillation (AF) in real-life outpatient practice on the territory of Kirov Region. MATERIALS AND METHODS: The registry included 163 patients with AF who were undergoing rehabilitation following ACS (ACS occurred.
2018: Kardiologiia
https://www.readbyqxmd.com/read/29781069/dual-and-triple-antithrombotic-therapies-current-patterns-of-practice-and-controversies
#10
Mark Crowther, John Eikelboom
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients undergoing percutaneous coronary intervention (PCI). Despite low-quality evidence, triple antithrombotic therapy involving acetylsalicylic acid, clopidogrel and warfarin or non-vitamin K antagonist oral anticoagulant (NOAC) has been recommended in patients with concomitant atrial fibrillation undergoing PCI, who require long-term oral anticoagulation, although such strategy is associated with a substantially increased risk of bleeding compared with DAPT...
May 21, 2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29768158/-issues-of-antithrombotic-therapy-in-acs-patients-with-atrial-fibrillation
#11
N A Kaydalova, L Y Koroleva, G V Kovaleva, N N Paykova, V P Nosov, A T Volkova, A M Koryazina
The review analyzed current ideas on prevalence and clinical significance of atrial fibrillation following acute coronary syndrome; described modern approaches to administration of antithrombotic therapy; and addressed available clinical studies on the treatment with warfarin and new oral anticoagulants as a part of combination antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome.
2018: Kardiologiia
https://www.readbyqxmd.com/read/29762881/colchicine-a-microtubule-disassembling-drug-in-the-therapy-of-cardiovascular-diseases
#12
George N Chaldakov
Colchicum autumnale, from which colchicine has been isolated more than 100 years ago, has been used as a treatment for pain and swelling for thousands of years. It is one of the few drugs known from that time period whose use has survived to modernity. Over the past decades, advances in the knowledge of (i) cytoskeletal microtubules (МТ), and (ii) anti-inflammatory and anti-fibrotic effects of colchicine, a classical MT-disassembling (tubulin-targeting) agent, have led to potential new uses for this very old drug extended beyond acute gouty arthritis and familial Mediterranean fever...
May 15, 2018: Cell Biology International
https://www.readbyqxmd.com/read/29724348/participation-of-women-in-clinical-trials-supporting-fda-approval-of-cardiovascular-drugs
#13
Pamela E Scott, Ellis F Unger, Marjorie R Jenkins, Mary Ross Southworth, Tzu-Yun McDowell, Ruth J Geller, Merina Elahi, Robert J Temple, Janet Woodcock
BACKGROUND: Concerns exist that women are underrepresented in trials of cardiovascular medications. OBJECTIVES: The authors sought to examine women's participation and the reported safety and efficacy by gender for pivotal cardiovascular disease (CVD) trials submitted to the U.S. Food and Drug Administration (FDA) supporting marketing applications. METHODS: On the basis of publicly available FDA reviews, the authors assessed enrollment of women in trials supporting 36 drug approvals from 2005 to 2015...
May 8, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29708956/optimal-management-of-cancer-patients-with-acute-coronary-syndrome
#14
Waldemar Banasiak, Robert Zymliński, Anetta Undas
Cancer at various stages and therapy is observed in about 15% of patients with acute coronary syndrome (ACS). Current guidelines for invasive and conservative treatment of ACS cannot be applied to all patients with cancer. The choice of antiplatelet and anticoagulant drugs should be individualized with clopidogrel as a key P2Y12 inhibitor in this population. Major challenges of therapy in patients with ACS and cancer include limitations for the use of the recommended antithrombotic therapy (particularly in case of cancer-related thrombocytopenia or when anticoagulation is needed due to concomitant atrial fibrillation or venous thromboembolism), the management of bleeding complications, eligibility criteria for cancer surgery, and reinitiation of chemotherapy or radiotherapy after ACS...
April 30, 2018: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29706432/increased-risk-of-ischemic-stroke-associated-with-new-onset-atrial-fibrillation-complicating-acute-coronary-syndrome-a-systematic-review-and-meta-analysis
#15
Jiachen Luo, Hongqiang Li, Xiaoming Qin, Baoxin Liu, Jinlong Zhao, Guli Maihe, Zhiqiang Li, Yidong Wei
BACKGROUND: Atrial fibrillation has been established as a major risk factor of ischemic stroke, however, the influence of new-onset atrial fibrillation (NOAF) complicating acute coronary syndrome (ACS) on ischemic stroke remains controversial. This meta-analysis aimed to validate the association between NOAF complicating ACS and ischemic stroke. METHODS: We identified randomized controlled trials and cohort studies comparing the ischemic stroke risk between patients with NOAF and sinus rhythm after ACS by searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials databases...
August 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29704565/antithrombotic-treatment-in-patients-with-acute-coronary-syndromes-and-atrial-fibrillation-what-is-established-and-what-is-missing
#16
EDITORIAL
Costas Tsioufis
No abstract text is available yet for this article.
January 2018: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
https://www.readbyqxmd.com/read/29672182/oral-anticoagulant-use-in-cardiovascular-disorders-a-perspective-on-present-and-potential-indications-for-rivaroxaban
#17
A John Camm, Keith A A Fox
BACKGROUND: Four non-vitamin-K-antagonist oral anticoagulants (NOACs) have been approved for use in various cardiovascular indications. The direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors apixaban, edoxaban and rivaroxaban are now increasingly used in clinical practice. For some of these agents, available data from real-world studies support the efficacy and safety data in phase III clinical trials. OBJECTIVES: This review aims to summarize the current status of trials and observational studies of oral anticoagulant use over the spectrum of cardiovascular disorders (excluding venous thrombosis), provide a reference source beyond stroke prevention for atrial fibrillation (AF) and examine the potential for novel applications in the cardiovascular field...
May 21, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29657061/risk-factors-for-new-onset-atrial-fibrillation-a-focus-on-asian-populations
#18
Yanguang Li, Daniele Pastori, Yutao Guo, Yutang Wang, Gregory Y H Lip
The incidence of new-onset atrial fibrillation (NOAF) is increasing both in the Asian populations and Western countries. Several demographic and clinical risk factors were independently associated with NOAF, including ageing, male sex, obesity, obstructive sleep apnea syndrome, hypertension, coronary artery disease, renal dysfunction and heart failure. However, some differences in the incidence of NOAF, the prevalence of some risk factors and lifestyle or environmental conditions may exist between Asian and Western countries...
June 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29652271/prophylactic-preoperative-levosimendan-for-off-pump-coronary-artery-bypass-grafting-in-patients-with-left-ventricular-dysfunction-single-centered-randomized-prospective-study
#19
Pushkar Mahendra Desai, Manjula S Sarkar, Sanjeeta R Umbarkar
Background: Off-pump coronary artery bypass surgery (OPCAB) is often complicated by hemodynamic instability, especially in patients with prior left ventricular (LV) dysfunction and appropriate choice of inotrope plays a vital role in perioperative management of these patients. Aim and Objective: To study hemodynamic effects and immediate outcome of prophylactic infusion of levosimendan in patients with the LV dysfunction undergoing OPCAB surgery and whether this strategy helps in successful conduct of OPCAB surgery...
April 2018: Annals of Cardiac Anaesthesia
https://www.readbyqxmd.com/read/29611427/impact-of-known-or-new-onset-atrial-fibrillation-on-2-year-cardiovascular-event-rate-in-patients-with-acute-coronary-syndromes-results-from-the-prospective-epicor-registry
#20
Uwe Zeymer, Lieven Annemans, Nicolas Danchin, Stuart Pocock, Simon Newsome, Frans Van de Werf, Jesús Medina, Héctor Bueno
BACKGROUND: Atrial fibrillation (AF) is associated with increased morbidity in acute coronary syndrome patients, but impact on outcomes beyond 1 year is unclear. METHODS: This was a post-hoc analysis from the long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry (NCT01171404), a prospective, observational study conducted in Europe and Latin America, which enrolled acute coronary syndrome survivors at discharge...
April 1, 2018: European Heart Journal. Acute Cardiovascular Care
keyword
keyword
98151
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"